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Objective:Althoughmitral restrictive annuloplasty plus coronary artery bypass grafting are considered the best ther-
apeutic strategies for ischemic cardiomyopathywith chronic mitral regurgitation, some recurrences are still reported.
We evaluated predictors for late recurrence of ischemic cardiomyopathy with chronic mitral regurgitation.
Methods: Hospital outcome and serial clinical and echocardiographic (preoperative, discharge, 6 months, end of
follow-up) follow-up assessments were recorded for 82 consecutive patients with ischemic cardiomyopathy with
chronic mitral regurgitation having coronary artery bypass graftingþmitral restrictive annuloplasty (2 sizes ring
downsizing). Recurrent ischemic cardiomyopathy with chronic mitral regurgitation was defined by grade  2 at
echocardiography.
Results: Hospital mortality was 4.9%; 17.7  1.7 (standard error) months (range 1–55) survival was 95.5% 
2.5%. Two-year Kaplan-Meier freedom from reintervention was 94.2%  4.2%; from rerevascularization,
87.5% 11.7%; fromcongestive heart failure, 83.8% 5.7%; from ischemic cardiomyopathywith chronicmitral
regurgitation grade 2, 46.5% 11.2%. Recurrenceof ischemic cardiomyopathywith chronicmitral regurgitation
gave lower 2-year Kaplan-Meier freedom fromdeath (P¼ .03) and lower 2-year freedom from congestive heart fail-
ure (P¼ .0001), reintervention (P¼ .034), and tricuspid insufficiency (P¼ .0001). Ischemic cardiomyopathy with
chronicmitral regurgitation recurrence correlatedwithworsenedNewYorkHeartAssociation class (P¼ .0001), left
ventricular ejection fraction (P¼ .024), pulmonary arterial pressures (P¼ .0001), left ventricular end-diastolic di-
ameter (P ¼ .004), left ventricular end-systolic diameter (P ¼ .014), indexed left ventricular mass (P ¼ .008), and
coaptation depth (P ¼ .0001). Independent predictors for recurrent ischemic cardiomyopathy with chronic mitral
regurgitation were previous anteriorþposterior myocardial infarction (odds ratio 3.70; confidence interval 2.93–
5.41; P¼ .001), preoperative left ventricular end-diastolic diameter 70 mm (odds ratio 3.91; confidence interval
2.65–5.22; P¼ .001), and coaptation depth at discharge 0.5 cm (odds ratio 11.9; confidence interval 5.91–21.34;
P ¼ .0001). Preoperative left ventricular end-diastolic diameter  70 mm correlated with higher congestive heart
failure (P ¼ .002), recurrent ischemic cardiomyopathy with chronic mitral regurgitation (P ¼ .0001), worsened
New York Heart Association class (P ¼ .0001), and higher diuretics (P ¼ .0001). Coaptation depth<0.5 cm at
discharge accounted for better survival (P ¼ .010), lower incidence of congestive heart failure (P ¼ .0001), lower
need for diuretics (P ¼ .0001), and improved New York Heart Association class (P ¼ .0001).
Conclusions: Failure of mitral restrictive annuloplasty is responsible for follow-upmortality and congestive heart
failure and correlates with absence of cardiac reverse remodeling. Prognosis of patients having mitral restrictive
annuloplasty for ischemic cardiomyopathy with chronic mitral regurgitation is good, as long as a low postoper-
ative coaptation depth is achieved. Patients with significant left ventricular dilation should be considered for dif-
ferent surgical strategies.Different animal and human studies suggested that patho-
genesis of ischemic chronic mitral regurgitation (ICMR) is
complex and is related to geometrical alterations of the left
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In particular, left ventricular sphericalization, annular en-
largement, increased tenting area, and loss of systolic mitral
annular contraction all contribute to the development of
ICMR.4 As ICMR results from multiple mechanisms, cur-
rent surgical therapy consisting of mitral restrictive annulo-
plasty (MRA) with an undersized annular ring does not
always provide durable repair.4
Different preoperative echocardiographic predictors of
ICMR recurrence have been described, ranging from ventric-
ular dilation,5 high sphericity index,6 high interpapillarygery c September 2009
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AMI ¼ acute myocardial infarction
CABG ¼ coronary artery bypass grafting
CD ¼ coaptation depth
CHF ¼ congestive heart failure
CPB ¼ cardiopulmonary bypass
ICMR ¼ ischemic chronic mitral regurgitation
LAD ¼ left atrial diameter
LVEDD ¼ left ventricular end-diastolic diameter
LVEF ¼ left ventricular ejection fraction
LVESD ¼ left ventricular end-systolic diameter
LVMi ¼ indexed left ventricular mass
mean Dp ¼ transmitral mean gradient
MRA ¼ mitral restrictive annuloplasty
MV ¼ mitral valve
NYHA ¼ New York Heart Association
PAP ¼ systolic pulmonary arterial pressure
TI ¼ tricuspid insufficiency grading
distance,7 coaptation depth (CD)>10 mm.8 All these data
suggest that surgery cannot effectively induce reverse re-
modeling of severely impaired ventricles. Accordingly,
recurrence of ICMR has been predominantly related to
progressive ventricular remodeling. Similarly, when MRA
fails, recurrent episodes of heart failure occur and follow-
up morbidity and mortality increase.9 However, literature
still lacks intraoperative or postoperative indexes anticipat-
ing MRA failure.
Therefore, it was the aim of the study to rule out indepen-
dent predictors of recurrent ICMR following MRA. Echo-
cardiographic and clinical outcomes in patients with
successful MRA or with MRA failure were also compared.
MATERIALS AND METHODS
Patients and Surgery
Between August 2004 and February 2008, 84 nonselected consecutive
patients admitted because of coronary disease and ICMR, having MRAþ
coronary artery bypass grafting (CABG), were enrolled in the study.Our Insti-
tutional ReviewBoard approved this study andwaived the need for individual
consent. All patients had ICMR grade 3þor 4þat preoperative echocardiogra-
phy. Patients demonstrating ICMR grade 2þ had intraoperative provocative
testing and were enrolled whenever 3þ to 4þ ICMR was evidenced. ICMR
was always due to postinfarction restrictive systolic leaflet motion (Carpentier
type IIIb), to severe annular dilation because of ischemic dilated cardiomyop-
athy (Carpentier type I), or to a combination of both (Carpentier type IþIIIb;
Table 1). Patients with concomitant surgical procedures (apart from tricuspid
annuloplasty) were excluded. Accordingly, patients with tricuspid regurgita-
tion grade 2 or tricuspid regurgitation<2þin the presence of dilated tricus-
pid annulus exceeding 21mm/m2 indexed to body surface area at transthoracic
echocardiography always had tricuspid annuloplasty.
All patients had symptoms of heart failure, and the majority presented in
New York Heart Association (NYHA) class III or IV (Table 1). Both elec-
tive and nonelective patients were enrolled. Mean logistic European System
for Cardiac Operative Risk Evaluation (EuroSCORE) was 8.3  1.5. Base-
line characteristics are presented in Table 1.The Journal of Thoracic and CSurgery was performed by the same surgeon (A.R.) through a median
sternotomy. The ascending aorta was always cannulated, and the venous re-
turn was always accomplished through a double caval cannulation. CABG
was constructed as already reported.10 The mitral valve was exposed
through longitudinal atriotomy along the Waterston’s groove in all patients.
Ring size (Carpentier-Edwards Physio ringor Carpentier-McCarthy-Adams
ring; both Edwards LifeSciences, Irving, Calif) was determined after mea-
surement of the height of the anterior leaflet and intertrigonal distance,
and then downsizing by 2 sizes (ie, size 26 when measuring 30). Complete
symmetric rings (Carpentier-Edwards Physio rings) were preferred when
ICMR was predominantly due to annular dilation (Carpentier type I), and
complete asymmetric rings (Carpentier-McCarthy-Adams rings) were
used when inferior or posterolateral infarction caused restrictive systolic
leaflet motion (Carpentier type IIIb). Tricuspid annuloplasty was always ac-
complished with a Carpentier Edwards MC3 ring (Edwards Lifesciences).
Cardiopulmonary bypass (CPB) was standardized and conducted as already
reported.10
Echocardiography
Echocardiography was always performed by the same 2 cardiologists,
blinded toward the surgical technique, using a VIVID 7 Pro ultrasound ma-
chine (GE Technologies, Milwaukee, Wis). All patients had transthoracic
TABLE 1. Preoperative and intraoperative data
Variables No. of patients
% of global
population
Age (y) 70.2  3.8 —
Sex (male) 54 65.8
EUROscore 8.3  1.5 —
NYHA class 3.4  0.6 —
Canadian Class Score 3.3  0.8 —
Diabetes 36 43.9
Hypertension 55 67.0
COPD 25 30.5
Left main stem disease 26 31.7
Previous AMI 51 62.2
Recent (<4 wk) AMI 42 51.2
Anterior AMI 10 12.1
Posterior AMI 57 69.5
Anteriorþposterior AMI 11 13.4
Emergency 3 3.6
UA/NSTEMI 31 37.8
STEMI 1 1.2
No. CABG 2.4  0.9 —
LITA CABG 82 100
Radial artery CABG 24 29.3
ACC time 73.6  4.5 —
CPB time 126.9  12.2 —
Tricuspid plasty 21 25.6
CABG Mean flow (mL/min) Pulsatility index
LITA–to–left anterior
descending
38.6  18.2 1.5  1.0
Radial artery 44.7  27.1 1.1  0.9
Saphenous vein 38.4  12.2 1.8  1.1
COPD, Chronic obstructive pulmonary disease; EuroSCORE, European System for
Cardiac Operative Risk Evaluation; AMI, acute myocardial infarction; UA/NSTEMI,
unstable angina/non-ST elevation myocardial infarction; CABG, coronary artery by-
pass graft; LITA, left internal thoracic artery; ACC, aortic crossclamp; CPB, cardiopul-
monary bypass.ardiovascular Surgery c Volume 138, Number 3 655
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follow-up, and at the end of the follow-up (mean 17.8  15.3 [standard
deviation] months; range 1–55 months). Follow-up was closed on March
30, 2008 and was 100% completed.
Transthoracic echocardiographic evaluation consisted of standard
echocardiography examination, including grading of the severity of
ICMR (semiquantitatively from color-flow Doppler), left atrial diameter
(LAD), left ventricular end-diastolic diameter (LVEDD), left ventricular
end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF),
indexed left ventricular mass (LVMi), CD, transmitral mean gradient
(mean Dp), systolic pulmonary arterial pressure (PAP), and tricuspid insuf-
ficiency grading (TI).
All patients also had intraoperative transesophageal echocardiography
assessment of left ventricular and valve function. MV repair was considered
successful if there was no residual mitral regurgitation following CPB dis-
continuation, with an adequate preload achieved (central venous pressure
between 10 and 15 mm Hg). Recurrence of ICMR was defined as grade
2þ/4þat semiquantitative color-flow Doppler analysis.
Clinical Assessment and Follow-up
Preoperative clinical status was determined according to the criteria of
the NYHA up to 5 days before surgery and was reassessed at discharge,
at 6 months, and at the end of follow-up. As a surrogate outcome of heart
failure, need and dose of furosemide were assessed at the same time points.
Deaths and episodes of acute congestive heart failure (CHF), redo mitral
surgery, and re-revascularization (either surgical or percutaneous) during
the follow-up were recorded.
Statistical Analysis
All data were prospectively recorded using the institutional database.
Statistical analysis was performed by the SPSS program for Windows, ver-
sion 13.0 (SPSS Inc, Chicago, Ill). Continuous variables are presented as
mean standard deviation, and categorical variables are presented as abso-
lute numbers and percentages. Data were checked for normality before sta-
tistical analysis. Normally distributed continuous variables were compared
using the unpaired t test, whereas the Mann-Whitney U test was used for
non-normally distributed variables. Categorical variables were analyzed us-
ing either the chi-square test or Fischer exact test. Comparisons between and
within groups were made using 2-way analysis of variance for repeated
measures. Univariate analyses of risk factors for recurrence of ICMR
were performed, calculating odds ratios with 95% confidence intervals.
Variables with aP value<.0001were consecutively subjected to amultivar-
iate logistic regression model to assess the independent impact of each risk
factor on recurrence of ICMR. A stepwise (backward Wald) multivariable
binary logistic regression analysis was used to test for predictors of recur-
rence of ICMR. Both regression model discrimination and calibration
were assessed by using the c-statistic for regression model discrimination
and the Hosmer-Lemeshow test statistic for model calibration.
Two-year freedoms from death, CHF, hospital readmission, and redo
surgery were determined with the method of Kaplan-Meier life table analy-
sis. Log-rank test was performed to ascertain differences between patients
with and without ICMR recurrence.
RESULTS
Preoperative and intraoperative data are reported in
Table 1.
Intraoperative Mitral Results
During the study period, 2 patients demonstrated persis-
tent intraoperative 1 to 2þ ICMR following CPB despite
2-size undersizing and had valve replacement following656 The Journal of Thoracic and Cardiovascular Sureestablishment of CPB. Therefore, these 2 patients were
excluded from the study because of the different surgical
therapy. The remaining 82 patients achieved a successful
MV repair and were definitively enrolled and followed.
Mean mitral ring size was 25.7 1.8 (median size 26; range
24–32). There were no cases of systolic anterior motion or
significant mitral stenosis (mean transvalvular gradient 4.5
 0.5 mm Hg; mean MV area 2.7  1.0 cm2). Twenty-
nine patients (35.3%) had tricuspid annuloplasty. Transit-
time flowmetry demonstrated good values in all CABG
(Table 1).
Hospital Outcome
Hospital mortality was 4.9% (4 patients). There were 1
perioperative acute myocardial infarction (AMI; 1.2%)
and 5 postoperative low output state (6.1%) requiring pro-
longed intra-aortic balloon pump (>48 hours) and inotropic
support with intravenous dobutamine and levosimendan;
transient paroxysmal atrial fibrillation requiring intravenous
amiodarone developed in 18 patients (21.9%). Three pa-
tients (3.6%) experienced respiratory failure because of
pneumonia, acute renal failure requiring renal replacement
therapy with continuous venovenous hemofiltration devel-
oped in 2 patients (2.4%), and cognitive dysfunction devel-
oped in 1 patient (1.2%). Overall hospital morbidity
accounted for 22 patients (26.8%). Intensive care stay was
43.4  9.1 hours (range 28–84 hours); hospital stay was
6.7  2.4 days. However, excluding the 4 patients who
died, all other patients completely recovered and were dis-
charged in healthy conditions.
Follow-up Clinical Outcome
Mean follow-up was 17.8  1.7 (standard error) months
(range 1–55 months). Three patients died during follow-up
because of acute CHF (n ¼ 2) and sudden death (n ¼ 1).
Both patients who died of CHF showed recurrence of
ICMR at follow-up. Therefore, the 2-year Kaplan-Meier
freedom from death was 96.5%  2.5% (Figure 1, A).
CHF developed in 9 patients during follow-up (2-year actu-
arial freedom from CHF 83.0% 5.7%; Figure 1, B), 2 pa-
tients needed redo mitral surgery (2-year actuarial freedom
from mitral reintervention 94.2%  4.2%; Figure 1, C),
and 1 patient had re-revascularization (2-year actuarial free-
dom from re-revascularization 87.5%  11.7%).
Twenty patients (25.6%) of 78 discharged from the hos-
pital had recurrent ICMR (grade  2) at echocardiographic
follow-up, resulting in a 2-year actuarial freedom from
ICMR of 46.5%  11.2% (Figure 1, D). However, when
patients with recurrent ICMR were compared with those
without ICMR, a significantly lower 2-year freedom from
death (log-rank P ¼ .0001; Figure 2, A), from CHF (log-
rank P ¼ .030; Figure 2, B), and from redo mitral surgery
(P ¼ .034; Figure 2, C) was demonstrated. Moreover, a sig-
nificant proportion of patients with preoperative severergery c September 2009
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Onorati et al Acquired Cardiovascular DiseaseFIGURE 1. Actuarial survival (A) and freedom from congestive heart failure (B), redo mitral surgery (C), re-revascularization (D).systolic impairment (LVEF<25%; 8 patients [9.7% of the
population]) had recurrent ICMR following surgery (recur-
rent ICMR 6/20 [30.0%] vs no recurrent ICMR 2/62
[3.2%]; P ¼ .002).
When functional status was considered, despite the fact
that both groups of patients (those with recurrent ICMR or
not) improved their NYHA class, those without ICMR dur-
ing follow-up showed a significantly better recovery of
NYHA class, together with a significantly lower need for
diuretics (Table 2). Accordingly, recurrent ICMR induced
progressive increase of the daily furosemide during the
follow-up (Table 2).
Echocardiographic Results
A completely different pattern of left and right ventricular
echocardiographic results was found in patients with recur-
rent ICMR and those without ICMR. In particular, patients
with recurrent ICMR showed absence of reverse remodeling
of LVEDD, LVESD, and LVMi, with a slight augmentation
of LAD (Table 3). Accordingly, LVEF did not improve
during the follow-up despite revascularization. TI grade
and PAP did not decrease despite MRA-reduced ICMRThe Journal of Thoracic and C(Table 3). MRA might have mimicked iatrogenic mild
stenosis, given the slight augmentation of the transmitral
mean Dp. Finally, after a significant amelioration of mitral
CD at discharge, CD increased parallel to the worsening of
ICMR, transmitral mean Dp progressive reduced, and PAP
and TI worsened (Table 3).
On the other hand, patients without recurrent ICMR
during the follow-up correlated with a significant reverse
remodeling of LVEDD, LVESD, LVMi, together with the
improvement of LVEF (Table 3). These same patients dem-
onstrated persistently shortened CD from discharge to the
end of follow-up and showed a higher mean Dp (compared
with patients with recurrent ICMR), with absence of LAD
reverse remodeling (Table 3). In this group of patients, TI
grade and PAP were reduced in parallel (Table 3).
Predictors of MRA Failure
Univariate analysis revealed that 23 of 45 recorded
variables had a significant (P< .05) association with recur-
rence of ICMR during the follow-up (see Appendix). Step-
wise logistic regression analysis revealed 3 variables
as independent predictors of ICMR recurrence: previousardiovascular Surgery c Volume 138, Number 3 657
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Acquired Cardiovascular Disease Onorati et alFIGURE 2. Survival (A), freedom from congestive heart failure (B), and mitral reintervention (C) between patients with ischemic chronic mitral regurgi-
tation recurrence and those without ischemic chronic mitral regurgitation recurrence.anteriorþposterior myocardial infarction (odds ratio 3.70),
preoperative LVEDD  70 mm (odds ratio 3.91), and CD
at discharge  0.5 cm (odds ratio 11.9; Table 4). The
discrimination
c-statistic for the final logistic regression analysis was 0.950,
suggesting that about 95% of the time, the model predicted
a correct response given a set of positive predictor variables.
The chi-square test result for the Hosmer-Lemeshow test
was 5.11 with 7 degrees of freedom, for an overall chi-
square significance of 0.646.
Stratification According to Postoperative CD<0.5
cm and LVEDD  70 mm
Subgroup analysis of patients stratified according to dis-
charge CD 0.5 cm or CD<0.5 cm revealed significant dif-
ferences in terms of major clinical end points. In particular,
patientswithCD<0.5 cmat discharge showed better survival658 The Journal of Thoracic and Cardiovascular Sur(log-rank P ¼ .010; Figure 3, A) and higher 2-year freedom
from CHF (log-rank P ¼ .0001; Figure 3, B). Accordingly,
patients with CD<0.5 cm demonstrated significantly better
NYHA class during the postoperative and follow-up time-
course (between-groups P ¼ .0001), with lower need for
daily furosemide (between-groups P ¼ .0001; Table 5).
Similarly, when patients were dichotomized according to
the preoperative left ventricular dilation, those with preoper-
ative LVEDD 70 mm showed a significantly lower 2-year
freedom from recurrent ICMR (10.3%  9.4% vs LVEDD
<70 mm 77.3%  13.1%; P ¼ .0001), with lower 2-year
freedom from CHF (53.9%  15.6% vs LVEDD< 70
mm 94.1%  3.3%, P ¼ .002). Furthermore, LVEDD 
70 mm correlated with a progressive worsening of NYHA
class during the follow-up (between-groups P ¼ .0001),
which paralleled a progressive increase of the daily diuretic
dose (between-groups P ¼ .0001, Table 5).TABLE 2. Recovery of NYHA class and need for daily dose of diuretics in patients with and without ICMR recurrence
Preoperative NYHA Discharge NYHA 6-mo NYHA Follow-up NYHA P* Py
ICMR 3.7  0.4 1.8  0.3 2.1  0.6 2.6  0.7 .0001 .0001
No ICMR 3.2  0.5 1.5  0.5 1.3  0.4 1.0  0.1 .0001
Preoperative daily
furosemide (mg)
Discharge daily
furosemide (mg)
6-mo daily
furosemide (mg)
Follow-up daily
furosemide (mg) P* Py
ICMR 92.2  45.7 42.3  13.6 59.4  28.4 82.1  28.5 .05 .0001
No ICMR 71.5  23.4 25.5  14.2 20.2  11.2 13.2  8.5 .0001
ICMR, Ischemic chronic mitral regurgitation; NYHA, New York Heart Association. *Statistical probability within group; ystatistical probability between groups.gery c September 2009
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Preoperative ICMR Discharge ICMR 6-mo ICMR Follow-up ICMR P* Py
ICMR 3.5  0.6 1.2  0.4 1.8  0.4 2.5  0.5 .209 .0001
No ICMR 3.4  0.5 0.7  0.4 0.6  0.4 0.5  0.5 .0001
Preoperative LAD Discharge LAD 6-mo LAD Follow-up LAD P* Py
ICMR 46.1  5.7 46.3  5.9 46.9  5.5 46.1  10.6 .301 .101
No ICMR 45.6  3.4 45.5  3.2 44.7  3.6 44.3  3.8 .063
Preoperative LVEDD Discharge LVEDD 6-mo LVEDD Follow-up LVEDD P* Py
ICMR 67.1  8.2 67.0  8.0 67.6  8.2 67.7  8.0 .282 .004
No ICMR 63.9  4.9 62.4  4.9 61.4  4.8 60.5  5.2 .0001
Preoperative LVESD Discharge LVESD 6-mo LVESD Follow-up LVESD P* Py
ICMR 55.3  13.5 55.3  13.0 55.3  13.6 55.4  13.3 .773 .014
No ICMR 54.4  6.6 49.6  6.6 48.1  6.4 46.8  5.9 .0001
Preoperative LVMi Discharge LVMi 6-mo LVMi Follow-up LVMi P* Py
ICMR 145.3  19.2 145.4  19.5 145.8  20.2 146.2  19.1 .089 .008
No ICMR 138.7  20.2 138.5  19.9 136.2  19.6 134.6  19.3 .002
Preoperative LVEF Discharge LVEF 6-mo LVEF Follow-up LVEF P* Py
ICMR 38.1  8.7 35.2  8.0 36.1  9.7 36.3  8.9 .713 .024
No ICMR 40.1  6.8 37.8  6.9 42.7  6.8 44.9  7.2 .0001
Preoperative CD Discharge CD 6-mo CD Follow-up CD P* Py
ICMR 1.3  0.2 0.7  0.3 0.8  0.4 0.8  0.4 .001 .0001
No ICMR 1.3  0.2 0.4  0.2 0.4  0.1 0.5  0.2 .0001
Preoperative mean Dp Discharge mean Dp 6-mo mean Dp Follow-up mean Dp P* Py
ICMR 0.9  0.9 4.7  0.9 4.3  0.8 3.9  1.1 .001 .0001
No ICMR 0.9  0.8 5.6  1.3 5.7  1.2 5.8  1.3 .0001
Preoperative TI Discharge TI 6-mo TI Follow-up TI P* Py
ICMR 2.1  0.6 1.3  0.5 1.5  0.6 2.0  0.7 .544 .0001
No ICMR 1.9  0.5 1.1  0.2 1.1  0.2 1.1  0.4 .0001
Preoperative PAP Discharge PAP 6-mo PAP Follow-up PAP P* Py
ICMR 45.0  8.4 36.6  7.9 39.1  8.7 38.6  10.2 .110 .0001
No ICMR 38.1  6.4 31.3  5.9 29.6  5.5 28.8  5.6 .0001
ICMR, Ischemic chronic mitral regurgitation; LAD, left atrial diameter; LVEDD, left ventricular diastolic diameter; LVESD, left ventricular systolic diameter; LVMi, left ventricular
mass index; LVEF, left ventricular ejection fraction; CD, coaptation depth;Dp, pressure gradient; TI, tricuspid insufficiency; PAP, pulmonary arterial pressure systolic. *Statistical
probability within group; ystatistical probability between groups.DISCUSSION
ICMR is considered a common cause of post-AMI con-
gestive heart failure, and it is present in 10% to 20% of pa-
tients with coronary artery disease.11 Moreover, it has been
considered one of the few targets for therapeutic opportuni-
ties in heart failure.11 According to the complex and differ-
ent pathogenetic mechanisms underlying such disease,
a number of different surgical techniques have been devel-
oped for ICMR.1-4,11 Of all the procedures described,
MRA proved to be effective, safe, and reproducible.5-9,11
However, all these experiences reported some recurrences,
ranging from 15% to 30%, because of a different population
profile and follow-up.5,7,8,11 In our series, 20 patients
(25.6%) had MRA failure during follow-up, in line with
other reports. Moreover, a recent article, examining 585The Journal of Thoracic and Cpatients over a 17-year period, found that recurrences devel-
oped in 28% of patients at 6 months.12
The main cause of early failure seems consequential to the
action of MRA only at the annular level, whereas it does not
fully address the ventricular causes of ICMR.11,12 Therefore,
TABLE 4. Independent predictors of recurrence of ICMRanalyzed by
multivariate logistic regression analysis
Variables
Odds
ratio
Confidence
limit (95%) P
Anteriorþposterior AMI 3.70 2.93–5.41 .001
Preoperative LVEDD  70 mm 3.91 2.65–5.22 .001
CD at discharge  0.5 cm 11.9 5.91–21.34 .0001
ICMR, Ischemic chronic mitral regurgitation; AMI, acute myocardial infarction;
LVEDD, left ventricular end-diastolic diameter; CD, coaptation depth.ardiovascular Surgery c Volume 138, Number 3 659
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Acquired Cardiovascular Disease Onorati et alFIGURE 3. Survival (A) and freedom from congestive heart failure (B) between patients with coaptation depth  0.5 cm at discharge and those with
coaptation depth<0.5 cm at discharge.the progressive ventricular dilation and the ongoing cardio-
myopathy act for late recurrences during the follow-up.5-8,13
All these factors have led surgeons to identify the predictors
for recurrence of ICMR despite MRA. Most of these predic-
tors are preoperative characteristics, such as CD>10 mm,8
preoperative LVEDD>65 mm,14 short posterior tethering,15
and interpapillary distance> 20 mm.7 However, literature
lacks early predictors of ICMR recurrence following MRA.
Our data confirmprevious reports14 showing preoperative en-
larged LVEDD (70 mm in our experience) to predict MRA
failure. Accordingly, preoperative LVEDD  70 mm corre-
lated with lower 2-year freedom from CHF and worsened
NYHA class. Moreover, we further found that CD  0.5
cm at discharge predicted the recurrence of ICMR. Therefore,
the identification of a CD 0.5 cm may help early detection
of a higher risk for recurrences. This finding therefore should
lead physicians to be more aggressive with medical therapy,
to be closer on patient’s follow-up, or to consider different
strategies.5 In our experience,CD 0.5 cm is themost power-
ful predictor of recurrent ICMR despite MRA. Furthermore,660 The Journal of Thoracic and Cardiovascular Sucompared with the preoperative predictors of ICMR already
reported,7,8,14,15 CD at discharge is certainly related to the
preoperative degree of postischemic left ventricular spherica-
lization,1,2,4 but it may also reflect a slightly less stringent sep-
tolateral cinching during the surgical time.16 Furthermore,
dichotomizing patients on the basis of their discharge CD,
we found that those with CD  0.5 cm had poorer survival
and lower 2-year freedom from CHF, with worsening
NYHA class and progressive decompensation. Accordingly,
they needed also higher doses of daily furosemide.
It is well known that patients with ICMR have a worse
natural history: the SAVE study demonstrated that patients
with mild ICMR had an increased risk of cardiovascular
mortality (29% vs 12%) and heart failure (24% vs 16%)
at 3.5 years after AMI compared with patients without
ICMR. Adjustment for differences in baseline characteristics
revealed thatmild tomoderate ICMR strongly predictedmid-
termmortality.17 Therefore, it was not surprising that patients
with recurrent ICMR showed lower 2-year freedom from
death, CHF, and redo mitral surgery, together withTABLE 5. Recovery of NYHA class and need for daily diuretic dose in patients with and without preoperative LVEDD  70 mm or with and
without CD  0.5 cm at discharge
Preoperative NYHA Discharge NYHA 6-mo NYHA Follow-up NYHA P* Py
Preoperative LVEDD  70 mm 3.6  0.5 1.8  0.4 1.9  0.6 2.4  1.0 .005 .0001
Preoperative LVEDD<70 mm 3.3  0.6 1.6  0.5 1.5  0.6 1.1  0.5 .0001
Preoperative daily
furosemide (mg)
Discharge daily
furosemide (mg)
6-mo daily
furosemide (mg)
Follow-up daily
furosemide (mg) P* Py
Preoperative LVEDD  70 mm 93.9  51.6 37.5  16.8 53.1  32.9 72.9  37.6 .007 .0001
Preoperative LVEDD<70 mm 73.9  25.7 30.9  11.7 24.2  13.8 20.9  20.7 .0001
Preoperative NYHA Discharge NYHA 6-mo NYHA Follow-up NYHA P* Py
Discharge CD  0.5 cm 3.6  0.5 1.8  0.4 1.9  0.7 2.3  0.9 .002 .0001
Discharge CD<0.5 cm 3.3  0.5 1.6  0.5 1.4  0.4 1.1  0.4 .0001
Preoperative daily
furosemide (mg)
Discharge daily
furosemide (mg)
6-mo daily
furosemide (mg)
Follow-up daily
furosemide (mg) P* Py
Discharge CD  0.5 cm 91.6  49.7 38.3  15.9 55.0  30.2 72.5  37.2 .001 .0001
Discharge CD<0.5 cm 74.4  25.3 30.2  11.3 21.5  8.7 17.4  13.4 .0001
CD, Coaptation depth; LVEDD, left ventricular end-diastolic diameter; NYHA, New York Heart Association. *Statistical probability within group; ystatistical probability between
groups.rgery c September 2009
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uretics, when compared with patients with recurrent ICMR.
Given the higher prevalence of recurrent ICMR when high
CD is found, patients with discharge CD  0.5 share the
same outcome. Our findings correlated with those of De Bo-
nis18 showing a significantly worse NYHA class when
ICMR recurred and those of Gelsomino,6 who found higher
NYHAclass and reoperation rate whenMRA failed. Accord-
ingly, Braun and colleagues14 showed that recurrent ICMR
reduces survival without ventricular reverse remodeling.
When echocardiographic results are considered, we found
a different fate of the left ventricle, based on the midterm
efficacy of MRA. Failed MRA resulted in recurrent ICMR
and therefore did not correlate with any left ventricular
reverse remodeling. On the contrary, successful MRA cured
ICMR, correlating with reverse remodeling of LVEDD,
LVESD, LVMi, together with improved LVEF and right
ventricular function, as demonstrated by the amelioration
of TI grade and PAP. Therefore, it was not surprising that pa-
tients with recurrent ICMR showed worsening functional
class and a need for higher daily doses of diuretics. These
data agreewith themajority of the literature reports, all show-
ing worsened survival and functional deterioration when
ICMR reccurs.5-8,11-13 In fact, it is noteworthy that Bolling
and associates19 first reported NYHA class amelioration fol-
lowing MRA in old ischemic patients in the early 1990s.
Since then, recurrences of mitral regurgitation dramatically
impacted follow-up survival, despite continuous improve-
ments of the surgical and medical therapies.20 Bax and
coworkers21 already demonstrated that effective MRA in-
duced left ventricular and left atrial reverse remodeling.
Our data confirm those of Bax and colleagues only when
left ventricular remodeling was considered. However, we
did not found reverse remodeling of the left atrial chamber,
even in patients without recurrent ICMR. These results could
possibly be related to the highermean transmitral gradients of
patients with successful MRA compared with those with
MRA failure. Accordingly, a recent report from Magne and
associates22 reported MRA to have the potential to induce
variable degrees of iatrogenic functional mitral stenosis. Cer-
tainly,more studies addressing such topics are needed to clar-
ify the potential deleterious effects of MRA. Finally, we
found that combined anteriorþposterior myocardial infarc-
tion also predicted midterm failure of MRA. It has been es-
tablished that evolution of ICMR involves complex
interactions between leaflets, annulus, chordate tendineae,
papillary muscles, and so on.1,2,11 Complex phenomena con-
tributed to ICMR, ranging from posterior papillary muscle
dislodgement, anterior and posterior annular dilation, loss
of the saddle shape and systodiastolic movements of the
annular plane, chordal and papillary muscle tethering action
on both leaflets, and so on.23 Lateral displacement of the pos-
terior papillary muscle appears to play a major role in the de-
velopment of ICMR following inferior AMI.23 Small infarctsThe Journal of Thoracic and Cin the area of posterior papillary muscle can lead to significant
ICMR.24However, froma functional point of view, it has been
demonstrated that the degree of functionalmitral regurgitation
is determined bymitral tenting, which is directly related to the
displacement of the papillarymuscles.25 In particular, not only
posterior but also apical displacements of both anterior and
posterior papillary muscles enhance ICMR.11,25 Similarly,
left ventricular distortion and remodeling after an anterior in-
farction displace papillary muscles toward the apex, resulting
in apical mitral tethering and restriction of coaptation during
systole.26 Moreover, left ventricular restoration in patients
with dyskinetic or aneurysmatic left ventricles may often re-
store the mitral competence.26 Therefore, it is not surprising
that patients with either anterior or posterior AMI during their
lives had extended and complex preoperative ventricular re-
modeling. In these patients, further surgical strategies other
than MRA should be considered to completely address the
complex pathogenesis underlying their ICMR.
Therefore,we conclude thatMRAfailure is responsible for
follow-upmortality and CHF and correlates with the absence
of reverse remodeling of the ventricular chamber. Prognosis
of patients having MRA in ICMR is good, as long as a low
postoperative CD is achieved. Patients with preoperative sig-
nificant left ventricular dilation exceeding 70mmof LVEDD
or with extensive preoperative left ventricular remodeling
because of multiple anterior and posterior infarcts should be
considered for complementary surgical strategies.
Limitations of the Study
Themain limitation of the study is the small sample size of
patients enrolled.This results from the single-center designof
the study, which, on the other hand, guarantees uniformity of
the surgical technique and perioperative care. The 100% fol-
low-up is also a strength. Another limitation is the relatively
low number of recurrent ICMR during the follow-up, which
may limit the efficacy of a multivariable analysis, where an
acceptedruleofthumbistoinclude1variableforconsideration
for every 10 outcomes of interest. However, we have tried to
limit the risk of anoverfittedmodel by including in the logistic
regressiononlythosevariables(n¼8)withahighlysignificant
correlation (P<.0001) with recurrent ICMR. In this way, the
multivariable model proved reliable, given a c-statistic of
0.950 and a Hosmer-Lemeshow’s goodness-of-fit P of .646.
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predictors of ICMR recurrence
Variables
ICMR
recurrence
No ICMR
recurrence P
Age 69.9  2.8 70.9  4.0 .711
EUROscore 8.1  1.2 8.3  1.6 .522
Sex (male) 13 (65.0%) 41 (71.9%) .376
Diabetes 16 (80.0%) 20 (35.1%) .001
Hypertension 15 (75.0%) 39 (68.4%) .401
Dyslipidemia 5 (25.0%) 15 (26.3%) .580
COPD 8 (40.0%) 17 (29.8%) .285
UA/NSTEMI 10 (50.0%) 21 (36.8%) .221
STEMI 0 (0%) 1 (1.8%) .740
Previous AMI 11 (55.0%) 39 (68.4%) .208
Recent AMI 17 (85.0%) 25 (43.9%) .001
Anterior AMI 5 (25.0%) 5 (8.8%) .075
Posterior AMI 6 (30.0%) 51 (89.4%) .0001
Anteriorþposterior AMI 9 (45.0%) 2 (3.6%) .0001
LMSD 10 (50.0%) 16 (27.6%) .061
Preoperative NYHA 3.7  0.4 3.2  0.5 .0001
Preoperative diuretics 92.2  45.7 71.5  23.4 .022
Preoperative ICMR 3.5  0.6 3.4  0.5 .037
Preoperative TI 2.1  0.6 1.9  0.5 .441
Preoperative PAP 45.0  8.4 38.1  6.4 .047
Preoperative LAD 46.1  5.7 45.6  3.4 .202
Preoperative LVEDD 67.1  8.2 63.9  4.9 .008
Preoperative LVEDD
>70 mm
14 (73.7%) 4 (7.0%) .0001
Preoperative LVESD 55.3  13.5 54.4  6.6 .028
Preoperative LVMi 145.3  19.2 138.7  20.2 .069
Preoperative LVEF 38.1  8.7 40.1  6.8 .174
APPENDIX. Continued
Variables
ICMR
recurrence
No ICMR
recurrence P
Preoperative CD 1.3  0.2 1.3  0.2 .501
Preoperative transmitral Dp 0.9  0.9 0.9  0.8 .693
No. CABG 2.0  1.1 2.5  0.9 .040
Tricuspid plasty 3 (15.0%) 13 (22.8%) .348
ACC time (min) 73.4  4.8 73.7  4.5 .832
CPB time (min) 138.7  15.7 136.3  10.8 .450
Discharge NYHA 1.8  0.3 1.5  0.5 .031
Discharge diuretics 42.3  13.6 25.5  14.2 .004
Discharge ICMR 1.2  0.4 0.7  0.4 .0001
Discharge TI 1.3  0.5 1.1  0.2 .533
Discharge PAP 36.6  7.9 31.3  5.9 .025
Discharge LAD 46.3  5.9 45.5  3.2 .063
Discharge LVEDD 67.0  8.0 62.4  4.9 .001
Discharge LVESD 55.3  13.0 49.6  6.6 .010
Discharge LVMi 145.4  19.5 138.5  19.9 .050
Discharge LVEF 35.2  8.0 37.8  6.9 .048
Discharge CD 0.7  0.3 0.4  0.2 .0001
Discharge CD  0.5 cm 18 (90.0%) 3 (5.3%) .0001
Discharge transmitral Dp 4.7  0.9 5.6  1.3 .0001
Redo mitral surgery 2 (10.0%) 0 (0%) .065
Re-revascularization 0 (0%) 1 (1.8%) .740
COPD, Chronic obstructive pulmonary disease; EuroSCORE, European System for
Cardiac Operative Risk Evaluation; UA/NSTEMI, unstable angina/non-ST elevation
myocardial infarction; STEMI, ST elevation myocardial infarction; AMI, acute myo-
cardial infarction; LMSD, left main stem disease;NYHA,NewYork Heart Association;
ICMR, chronic mitral regurgitation; TI, tricuspid insufficiency; PAP, systolic pulmo-
nary arterial pressure; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic
diameter; LVESD, left ventricular end-systolic diameter; LVMi, indeed left ventricular
mass; LVEF, left ventricular ejection fraction; CD, coaptation depth; CABG, coronary
artery bypass grafting; ACC, aortic crossclamp; CPB, cardiopulmonary bypass.gery c September 2009
